KRAS specific TCR-T Cell Therapy / Shanghai Bintie Biotech - LARVOL DELTA

KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials (THE ASCO POST) - "Although adagrasib monotherapy had a higher overall response rate and longer progression-free and overall survival than previously reported with sotorasib monotherapy, it is important to note some differences in the populations investigated. In the CodeBreaK100 trial, 100% of patients treated with sotorasib monotherapy received oxaliplatin, irinotecan, and a fluoropyrimidine prior to study enrollment, whereas 77% of the adagrasib monotherapy population were exposed to all three drugs."

Online posting